NCT06870279Not yet recruitingPhase 1
A Clinical Research of CD70-targeted CAR-NKT Cells (CGC738) Therapy in RCC
A Clinical Research Evaluating the Safety and Efficacy of CD70-targeted CAR-NKT Cells (CGC738) Therapy in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Source: ClinicalTrials.gov · Last updated 24 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a phase I, open-label, single-arm study conducted to evaluate the efficacy, safety and PK of CGC738 in the treatment of advanced clear cell renal cell carcinoma (ccRCC).
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (estimated)
- First submitted
- 5 Mar 2025
- Start date
- 25 May 2025
- Primary completion date
- 1 Aug 2026
- Lead sponsor
- RenJi Hospital
- Diseases
- Kidney cancer
- NCT number
- NCT06870279
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 28
- From 25 May 2025 to the primary completion date, 1 Aug 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- 1\. Use of cell therapy within the previous one month.
- 4\. Immunotherapy, targeted drug therapy or chemotherapy within 5 drug half-lives within 2 weeks before cell infusion.
- 11.Subjects who are using systemic steroids or steroid inhalers for treatment.
Other illness
- 2\. Subjects with other malignant tumors within the past 2 years, except basal or squamous skin cancer, superficial bladder cancer, and breast cancer in situ, have been completely cured and do not need follow-up treatment.
- 3\. Patients with leptomeningeal metastasis or central nervous system metastasis, and definite central nervous system underlying diseases with significant symptoms.
- 5\. Active hepatitis B, HIV positive and HCV positive.
- 6\. Active infection or uncontrollable infection.
- 7\. Uncontrollable or significant heart disease.
- 8\. Unstable respiratory diseases, including interstitial pneumonia.
- 10.Known to have active or uncontrolled autoimmune diseases, such as Crohns disease, rheumatoid arthritis, systemic lupus erythematosus, etc.
Other
- 9\. Uncontrolled ascites and pleural effusion.
- 12.Pregnant or lactating female subjects.
- 13.Other investigators deem it unsuitable to participate in the study
Who the study is looking for
- 1\. Age 18 to 75 years.
- 2.ECOG 0-1 points.
- 3\. The expected survival time is more than 3 months.
- 4\. Patients with advanced ccRCC confirmed by histology or cytology to be recurrent or metastatic after at least first-line treatment.
- 5\. IHC: CD70 positive.
- 6\. At least one measurable lesion at baseline per RECIST version 1.1.
- 7\. The functions of important organs are basically normal:
- 8\. Pregnancy tests for women of childbearing age shall be negative, both men and women agreed to use effective contraception.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.